<DOC>
	<DOCNO>NCT00006246</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study safety deliver intrathecal busulfan child adolescents refractory CNS cancer estimate maximum tolerate dose treatment regimen .</brief_summary>
	<brief_title>Busulfan Treating Children Adolescents With Refractory CNS Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine qualitative quantitative toxicity intrathecally administer busulfan child adolescents refractory CNS malignancy . - Determine maximum tolerate dose treatment regimen patient . - Determine cerebrospinal fluid serum pharmacokinetics treatment regimen patient . - Determine efficacy treatment regimen patient . OUTLINE : This dose-escalation study . Patients receive intrathecal busulfan twice week , least 3 day apart , 2 week . Patients complete partial response stable disease may continue therapy week 2 week , week every week 2 treatment , month thereafter absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos busulfan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 3 month first year , every 6 month 4 year , annually 5 year . PROJECTED ACCRUAL : Approximately 18-24 patient accrue study 18-38 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CNS malignancy , include follow : Primary malignant brain tumor refractory standard therapy metastatic cerebrospinal fluid ( CSF ) leptomeningeal subarachnoid space Recurrent persistent leptomeningeal leukemia , lymphoma , germ cell tumor refractory conventional therapy In second great relapse CSF white blood count great 5 cells/mm3 blast cytospin OR Evidence leptomeningeal tumor MRI No concurrent bone marrow disease No obstruction compartmentalization CSF flow CSF flow study PATIENT CHARACTERISTICS : Age : 3 21 Performance status : Lansky 50100 % ( 10 year ) Karnofsky 50100 % ( 10 21 year ) Life expectancy : Greater 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 75,000/mm^3 Hepatic : Bilirubin normal age ALT AST less 5 time upper limit normal ( ULN ) No hepatic disease Renal : Creatinine great 1.5 time ULN OR Glomerular filtration rate great 70 mL/min No renal disease Cardiovascular : No cardiac disease Pulmonary : No pulmonary disease Other : No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) At least 1 week since prior intrathecal chemotherapy ( 2 week cytarabine ) recover Evidence subsequent disease progression Concurrent systemic chemotherapy allow recurrent disease first course treatment except follow : Chemotherapy target leptomeningeal disease Other phase I agent Any agent significantly penetrate CSF ( e.g. , high dose methotrexate great 1 g/m2 , thiotepa , high dose cytarabine , fluorouracil , IV mercaptopurine , nitrosoureas , topotecan ) Any agent cause serious unpredictable CNS side effect Endocrine therapy : Prior dexamethasone allow decrease stable dose least one week study Concurrent dexamethasone prednisone chemotherapy regimen allow Radiotherapy : At least 1 week since prior focal irradiation brain spine At least 8 week since prior craniospinal irradiation No concurrent cranial craniospinal irradiation Surgery : Not specify Other : No concurrent intrathecal systemic therapy leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
</DOC>